Benefit of aggressive prostate CA Tx weakens as comorbidity rises

Benefit of aggressive prostate CA tx weakens as comorbidity rises

(HealthDay)—For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study published online May 13 in Cancer.

Timothy J. Daskivich, M.D., from the University of California in Los Angeles, and colleagues compared the effectiveness of aggressive versus nonaggressive treatment for reducing cancer-specific in a cohort of 140,553 men aged ≥66 years with early-stage . Data for participants, diagnosed between 1991 and 2007, were extracted from the Surveillance, Epidemiology, and End Results-Medicare database.

The researchers found that, among men with Charlson scores of 0, 1, and 2, but not among those with scores of ≥3, aggressive treatment correlated with a reduced risk of cancer-specific mortality (subhazard ratio for Charlson score ≥3, 0.85; 95 percent confidence interval, 0.62 to 1.18) in propensity-adjusted competing-risks regression analysis. For men with Charlson scores of 0, 1, 2, and ≥3, the absolute reduction in 15-year cancer-specific mortality between men who received aggressive versus nonaggressive treatment was 6.1, 4.3, 3.9, and 0.9 percent, respectively. Aggressive treatment correlated with a lower risk of cancer-specific mortality among men who had well-differentiated and moderately-differentiated tumors with Charlson scores of 0, 1, and 2, but not ≥3 (subhazard ratio for Charlson score ≥3, 1.14; 95 percent confidence interval, 0.70 to 1.89). When considering only well- and moderately-differentiated tumors, the absolute reduction in 15-year cancer-specific mortality was 3.8, 3.0, 1.9, and −0.5 percent for men with Charlson scores of 0, 1, 2, and ≥3, respectively.

"The cancer-specific from for early-stage prostate cancer diminishes with increasing comorbidity at diagnosis," the authors write.

One author is a cofounder of Wiser Care.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Implications of very low risk prostate cancer assessed

Sep 20, 2013

(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...

Recommended for you

Gene test aids cancer profile

5 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

22 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.